Literature DB >> 31616070

Is there a duty to reinterpret genetic data? The ethical dimensions.

Paul S Appelbaum1, Erik Parens2, Sara M Berger3, Wendy K Chung4, Wylie Burke5.   

Abstract

The evolving evidence base for the interpretation of variants identified in genetic and genomic testing has presented the genetics community with the challenge of variant reinterpretation. In particular, it is unclear whether an ethical duty of periodic reinterpretation should exist, who should bear that duty, and what its dimensions should be. Based on an analysis of the ethical arguments for and against a duty to reinterpret, we conclude that a duty should be recognized. Most importantly, by virtue of ordering and conducting tests likely to produce data on variants that cannot be definitively interpreted today, the health-care system incurs a duty to reinterpret when more reliable data become available. We identify four elements of the proposed ethical duty: data storage, initiation of reinterpretation, conduct of reinterpretation, and patient recontact, and we identify the parties best situated to implement each component. We also consider the reasonable extent and duration of a duty, and the role of the patient's consent in the process, although we acknowledge that some details regarding procedures and funding still need to be addressed. The likelihood of substantial patient benefit from a systematic approach to reinterpretation suggests the importance for the genetics community to reach consensus on this issue.

Entities:  

Keywords:  ELSI; genetic testing; reinterpretation

Mesh:

Year:  2019        PMID: 31616070      PMCID: PMC7185819          DOI: 10.1038/s41436-019-0679-7

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  13 in total

Review 1.  Transcriptome analysis provides critical answers to the "variants of uncertain significance" conundrum.

Authors:  Mackenzie D Postel; Julie O Culver; Charité Ricker; David W Craig
Journal:  Hum Mutat       Date:  2022-05-18       Impact factor: 4.700

2.  Exome/Genome-Wide Testing in Newborn Screening: A Proportionate Path Forward.

Authors:  Vasiliki Rahimzadeh; Jan M Friedman; Guido de Wert; Bartha M Knoppers
Journal:  Front Genet       Date:  2022-07-04       Impact factor: 4.772

3.  Artificial Intelligence-Assisted Serial Analysis of Clinical Cancer Genomics Data Identifies Changing Treatment Recommendations and Therapeutic Targets.

Authors:  Catherine G Fischer; Aparna Pallavajjala; LiQun Jiang; Valsamo Anagnostou; Jessica Tao; Emily Adams; James R Eshleman; Christopher D Gocke; Ming-Tseh Lin; Elizabeth A Platz; Rena R Xian
Journal:  Clin Cancer Res       Date:  2022-06-01       Impact factor: 13.801

Review 4.  Genetic testing for kidney disease of unknown etiology.

Authors:  Thomas Hays; Emily E Groopman; Ali G Gharavi
Journal:  Kidney Int       Date:  2020-04-24       Impact factor: 10.612

Review 5.  Genetic testing for unexplained perinatal disorders.

Authors:  Thomas Hays; Ronald J Wapner
Journal:  Curr Opin Pediatr       Date:  2021-04-01       Impact factor: 2.856

6.  Genomic medicine and the "loss of chance" medical malpractice doctrine.

Authors:  Jennifer K Wagner; Michelle N Meyer
Journal:  HGG Adv       Date:  2021-04-05

Review 7.  Is Gene-Size an Issue for the Diagnosis of Skeletal Muscle Disorders?

Authors:  Marco Savarese; Salla Välipakka; Mridul Johari; Peter Hackman; Bjarne Udd
Journal:  J Neuromuscul Dis       Date:  2020

8.  iVar, an Interpretation-Oriented Tool to Manage the Update and Revision of Variant Annotation and Classification.

Authors:  Sara Castellano; Federica Cestari; Giovanni Faglioni; Elena Tenedini; Marco Marino; Lucia Artuso; Rossella Manfredini; Mario Luppi; Tommaso Trenti; Enrico Tagliafico
Journal:  Genes (Basel)       Date:  2021-03-08       Impact factor: 4.096

9.  Perceptions of best practices for return of results in an international survey of psychiatric genetics researchers.

Authors:  Gabriel Lázaro-Muñoz; Laura Torgerson; Hadley Stevens Smith; Stacey Pereira
Journal:  Eur J Hum Genet       Date:  2020-10-03       Impact factor: 4.246

10.  Solving patients with rare diseases through programmatic reanalysis of genome-phenome data.

Authors:  Leslie Matalonga; Carles Hernández-Ferrer; Davide Piscia; Rebecca Schüle; Matthis Synofzik; Ana Töpf; Lisenka E L M Vissers; Richarda de Voer; Raul Tonda; Steven Laurie; Marcos Fernandez-Callejo; Daniel Picó; Carles Garcia-Linares; Anastasios Papakonstantinou; Alberto Corvó; Ricky Joshi; Hector Diez; Ivo Gut; Alexander Hoischen; Holm Graessner; Sergi Beltran
Journal:  Eur J Hum Genet       Date:  2021-06-01       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.